GlassScriptPhysician profile
Carole C Aponte
NPI 1053374033
$6,180.97
in general payments reported to CMS, 2019-2025
35 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $183 · 2022: $714 · 2023: $1,407 · 2024: $1,268 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,483 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,482.57 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $862.26 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Janssen Biotech, INC. | $841.16 | 2019-2025 | Tremfya, Remicade, Stelara |
| Lilly USA, LLC | $721.96 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $394.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $369.24 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $368.84 | 2019-2025 | Winlevi |
| Leo Pharma INC. | $291.97 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $253.52 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Amgen INC. | $222.11 | 2020-2025 | Otezla, Otezla |
| Almirall LLC | $213.32 | 2019-2025 | Seysara, Klisyri |
| Incyte Corporation | $212.25 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $204.24 | 2019-2025 | |
| Pfizer INC. | $180.50 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $161.80 | 2019-2025 | Arazlo, Jublia, Cabtreo |
| Arcutis Biotherapeutics, INC. | $144.77 | 2023-2025 | Zoryve |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $118.99 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $93.38 | 2019-2025 | |
| Ucb, INC. | $80.32 | 2023-2025 | Cimzia, Bimzelx |
| Medimetriks Pharmaceuticals, INC. | $59.24 | 2025 | Neo-Synalar, Clindacin Etz |
| Allergan, INC. | $46.59 | 2019-2022 | |
| Dermira, INC. | $42.51 | 2019-2020 | |
| Sandoz INC. | $41.68 | 2019 | |
| Vyne Pharmaceuticals INC. | $34.03 | 2020 | |
| Dermavant Sciences, INC. | $27.41 | 2022-2023 | Vtama |
| Organon LLC | $23.32 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $22.86 | 2023 | Ycanth |
| Biofrontera INC. | $21.38 | 2020 | |
| Merz North America, INC. | $19.94 | 2022 | |
| Springworks Therapeutics, INC. | $17.98 | 2025 | Gomekli |
| Journey Medical Corporation | $17.80 | 2025 | |
| Botanix Sb INC | $17.75 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $15.41 | 2025 | Spinosad, Natroba |
| Nabriva Therapeutics, Plc | $13.45 | 2022 | |
| Dusa Pharmaceuticals, INC. | $12.97 | 2019 | |
| Merck Sharp & Dohme LLC | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carole Aponte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.